G-Quantum BIO SUMMIT 2026

G-Quantum BIO SUMMIT 2026

Title

Login Sign up Contact us
전체메뉴열기
Program
Industrial Track
  • Program at a glance
  • Main Summit
  • Academic Track
  • Standard Track
  • Clinical Track
  • Industrial Track
  • Speakers
Industrial Track
View the Program Go to Register
Day 2. (May 28, Thu) - (1F) Exhibition Hall 2
09:00-18:30
지식-산업 매칭 쇼케이스
Day 3. (May 29, Fri) - (1F) Exhibition Hall 2&3, (3F) Convention Hall 1~3
09:00-18:30
지식-산업 매칭 쇼케이스
09:00-09:50
Registration
Opening Remarks
09:50-10:00
Opening Remarks
Daehoon Kim
Chairman, KSNS
Session 1 Drug R&D Trends: Current landscape and future directions (Chair: Hyunju Sim / Professor, Jeonbuk University)
10:00-10:40
Navigating the future of drug innovation: Global trends and Korea's strategic path
Sun Nam Kim
CSO, R&D Division, KDDF
10:40-11:20
Innovating proximity - introducing therapeutics: Targeted protein degradation and beyond
Hakryul Jo
EVP, Yuhan Corporation
11:20-11:40
Booth Exhibition & Coffee Break
Session 2 Drug R&D Trends: Current landscape and future directions (Chair: Yonsik Choi / Professor, KOPO)
11:40-12:20
Grabbody-B, IGF1R-meditated BBB shuttle increase brain penetration of therapeutics
Sanghoon Lee Learn More
CEO / Founder, ABL Bio
Luncheon Seminar & Lunch Time
12:20-12:40
From Target to Clinic : Key Considerations in ADC Design and Translational Evaluation
Yinfei Yin
Ph.D, ChemOne
From Cells to Circuits: An Integrated Functional–Structural Interpretation Strategy in Mouse Retinal Research
Seonsook Baek
Director, Chaon
The Advances in Bispecific ADC and Challenges in Clinical Bioanalysis
Luke Bi
LabCorp
12:40-14:00
Booth Exhibition & Coffee Break
Session 3 Division Seminars
Session 3-1 Pharmacology (Chair: Juhee Lee / Division leader, KSNS)
14:00-14:30
Organoid-based nonclinical efficacy evaluation platforms: application and case studies
Jongman Yoo
President, Organoid Science
14:30-15:00
A new non-human primate (efficacy) preclinical model of agerelated macular degeneration
Dr. Aldric Hama
Hamamatsu Pharma Research
15:00-15:30
Development experience and applications of therapeutic organoid platforms
Hyejeong Park
VP, Cellincells
Session 3-2 Pharmacokinetics (Chair: Semi Kim / Division leader, KSNS)
14:00-14:30
Global nonclinical development optimization using AI and mechanistic modeling (PBPK/QSP): case studies and FDA trends
Junyong Lee
President, Certara
14:30-15:00
Utilization of model-based approaches to maximize efficacy of antibiotics for the treatment of mycobacterium abscessus pulmonary infections (Mab-PI)
Hyunseo Park
Team leader, LG chemical
15:00-15:30
Evaluating reactive metabolites-mediated DILI risk: workflow and regulatory response strategy
Jongcheol Son
Head of PK department, Daewoong pharmaceuticals
Session 3-3 Medcinal chemistry (Chair: Hyejung Kim / Division leader, KSNS)
14:00-14:30
Discovery of E3 ligase ligands for muscle specific protein degradation
Jongmin Park
Professor, Kangwon University
14:30-15:00
AUTOTAC platform technology and flagship pipeline for neurodegeneration diseases
Changhoon Ji
Director of R&D Institute, Autotac Bio
15:00-15:30
Discovery of potent and selective EP300 PROTAC degraders
Seokjong Kang
Head of TPD department, Hanmi pharma
Session 3-4 Toxicology (Chair: Jinsoo Lee / Division leader, KSNS)
14:00-14:30
Guidance and operational considerations for nonhuman primate studies in nonclinical development
Hyungsun Baek
Senior researcher, KIT
14:30-15:00
Nonclinical evaluation of advanced biopharmaceuticals in nonhuman primate models
Seonghoon Park
Director, Keyprime research
15:00-15:30
Advanced animal models using common Marmosets
Dohyun Lee
Senior manager, K-BIOHEALTH
15:30-16:00
Booth Exhibition & Coffee Break
Session 4 Future medicine: advancing and refining innovation (Chair: Sewoong Oh / Professor, Yonsei University)
16:00-16:40
SPIDEM: Pushing the boundaries of TPD
Kyung-soo Inn
CEO / Founder, Prazer Therapeutics
16:40-17:20
Advancing RNA Editing Therapeutics: Rznomics Pipeline and Global Development Strategy
Sungwoo Hong
VP, Rznomics
Closing Remarks
17:50-
Closing Remarks
Juyoung Cha
VC, KSNS